Aspects of Newborn Screening in Isovaleric Acidemia
Open Access
- 28 January 2018
- journal article
- review article
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 4 (1), 7
- https://doi.org/10.3390/ijns4010007
Abstract
Isovaleric acidemia (IVA), an inborn error of leucine catabolism, is caused by mutations in the isovaleryl-CoA dehydrogenase (IVD) gene, resulting in the accumulation of derivatives of isovaleryl-CoA including isovaleryl (C5)-carnitine, the marker metabolite used for newborn screening (NBS). The inclusion of IVA in NBS programs in many countries has broadened knowledge of the variability of the condition, whereas prior to NBS, two distinct clinical phenotypes were known, an “acute neonatal” and a “chronic intermittent” form. An additional biochemically mild and potentially asymptomatic form of IVA and its association with a common missense mutation, c.932C>T (p.A282V), was discovered in subjects identified through NBS. Deficiency of short/branched chain specific acyl-CoA dehydrogenase (2-methylbutyryl-CoA dehydrogenase), a defect of isoleucine degradation whose clinical significance remains unclear, also results in elevated C5-carnitine, and may therefore be detected by NBS for IVA. Treatment strategies for the long-term management of symptomatic IVA comprise the prevention of catabolism, dietary restriction of natural protein or leucine intake, and supplementation with l-carnitine and/or l-glycine. Recommendations on how to counsel and manage individuals with the mild phenotype detected by NBS are required.This publication has 84 references indexed in Scilit:
- Acute Pancreatitis with Rapid Clinical Improvement in a Child with Isovaleric AcidemiaCase Reports in Pediatrics, 2013
- Chronic intermittent form of isovaleric aciduria in a 2-year-old boyKorean Journal of Pediatrics, 2013
- Clinical and neurocognitive outcome in symptomatic isovaleric acidemiaOrphanet Journal of Rare Diseases, 2012
- Biochemical Monitoring and Management During Pregnancy in Patients with Isovaleric Acidaemia is Helpful to Prevent Metabolic DecompensationJIMD Reports, 2011
- Efficacy and outcome of expanded newborn screening for metabolic diseases - Report of 10 years from South-West Germany *Orphanet Journal of Rare Diseases, 2011
- Characterization of new ACADSB gene sequence mutations and clinical implications in patients with 2-methylbutyrylglycinuria identified by newborn screeningMolecular Genetics and Metabolism, 2010
- 2-methylbutyryl-CoA dehydrogenase deficiency associated with autism and mental retardation: a case reportJournal of Medical Case Reports, 2007
- Isovaleric acidemia: New aspects of genetic and phenotypic heterogeneitySeminars in Medical Genetics, Part C of the American Journal of Medical Genetics, 2006
- Maternal isovaleric acidemiaThe Journal of Pediatrics, 1984
- Glycine therapy in isovaleric acidemiaThe Journal of Pediatrics, 1978